Your browser doesn't support javascript.
loading
New proteasome inhibitors in the treatment of multiple myeloma.
Hungria, Vania Tietsche de Moraes; Crusoé, Edvan de Queiroz; Bittencourt, Rosane Isabel; Maiolino, Angelo; Magalhães, Roberto José Pessoa; Sobrinho, Jairo do Nascimento; Pinto, Jorge Vaz; Fortes, Ricardo Coutinho; Moreira, Eloisa de Sá; Tanaka, Paula Yurie.
Afiliación
  • Hungria VTM; Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil. Electronic address: hungria@dialdata.com.br.
  • Crusoé EQ; Universidade Federal da Bahia, Hospital Universitário Professor Edgar Santos, Serviço de Hematologia, Salvador, BA, Brazil.
  • Bittencourt RI; Hospital de Clínicas de Porto Alegre, Serviço de Hematologia, Porto Alegre, RS, Brazil.
  • Maiolino A; Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • Magalhães RJP; Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • Sobrinho JDN; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Pinto JV; Universidade Católica de Brasília, Brasília, DF, Brazil.
  • Fortes RC; Evidências - Kantar Health, São Paulo, SP, Brazil.
  • Moreira ES; Evidências - Kantar Health, São Paulo, SP, Brazil.
  • Tanaka PY; Takeda Pharma, São Paulo, SP, Brazil.
Hematol Transfus Cell Ther ; 41(1): 76-83, 2019.
Article en En | MEDLINE | ID: mdl-30793108
The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Hematol Transfus Cell Ther Año: 2019 Tipo del documento: Article Pais de publicación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Hematol Transfus Cell Ther Año: 2019 Tipo del documento: Article Pais de publicación: Brasil